Avalyn Pharma (NASDAQ:AVLN) Shares Gap Down – Time to Sell?

Avalyn Pharma Inc. (NASDAQ:AVLN)’s share price gapped down prior to trading on Monday . The stock had previously closed at $29.73, but opened at $28.25. Avalyn Pharma shares last traded at $28.37, with a volume of 1,744 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AVLN. Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Guggenheim started coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $80.00 price objective for the company. Evercore initiated coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They set a “buy” rating and a $52.00 target price on the stock. Finally, Morgan Stanley assumed coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $59.00.

Avalyn Pharma Price Performance

The stock has a fifty day moving average price of $28.74. The company has a market capitalization of $1.24 billion and a PE ratio of -1.28.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share for the quarter, missing the consensus estimate of ($16.38) by ($5.45).

Insider Activity at Avalyn Pharma

In related news, major shareholder Sr One Capital Management, Llc bought 555,555 shares of Avalyn Pharma stock in a transaction that occurred on Friday, May 1st. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. The trade was a 34.06% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jill Carroll bought 277,778 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This trade represents a 14.55% increase in their position. The disclosure for this purchase is available in the SEC filing.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.